{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:00:31Z","timestamp":1769155231397,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41416-018-0145-3","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T11:16:32Z","timestamp":1529320592000},"page":"65-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma"],"prefix":"10.1038","volume":"119","author":[{"given":"Duo","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-Qing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursina","family":"L\u00fcthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Riether","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Berezowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean R. R.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Bruggmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor J.","family":"Kocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph A.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-Wang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"key":"145_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jcp.22724","volume":"227","author":"M Carbone","year":"2012","unstructured":"Carbone, M. et al. Malignant mesothelioma: facts, myths, and hypotheses. J. Cell. Physiol. 227, 44\u201358 (2012).","journal-title":"J. Cell. Physiol."},{"key":"145_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12199-007-0017-6","volume":"13","author":"K Inai","year":"2008","unstructured":"Inai, K. Pathology of mesothelioma. Environ. Health Prev. Med. 13, 60\u201364 (2008).","journal-title":"Environ. Health Prev. Med."},{"key":"145_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"145_CR4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1476-5381.2012.01873.x","volume":"166","author":"RE Favoni","year":"2012","unstructured":"Favoni, R. E., Daga, A., Malatesta, P. & Florio, T. Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. Br. J. Pharmacol. 166, 532\u2013553 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"145_CR5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/bjc.2013.731","volume":"110","author":"A Linton","year":"2014","unstructured":"Linton, A. et al. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. Brit J. Cancer 110, 510\u2013519 (2014).","journal-title":"Brit J. Cancer"},{"key":"145_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636\u20132644 (2003).","journal-title":"J. Clin. Oncol."},{"key":"145_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","volume":"66","author":"R Jagadeeswaran","year":"2006","unstructured":"Jagadeeswaran, R. et al. Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66, 352\u2013361 (2006).","journal-title":"Cancer Res."},{"key":"145_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2217\/fon.12.14","volume":"8","author":"F Grosso","year":"2012","unstructured":"Grosso, F. & Scagliotti, G. V. Systemic treatment of malignant pleural mesothelioma. Future Oncol. 8, 293\u2013305 (2012).","journal-title":"Future Oncol."},{"key":"145_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nature17041","volume":"529","author":"M Wang","year":"2016","unstructured":"Wang, M. & Kaufman, R. J. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature 529, 326\u2013335 (2016).","journal-title":"Nature"},{"key":"145_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrc3800","volume":"14","author":"M Wang","year":"2014","unstructured":"Wang, M. & Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 14, 581\u2013597 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"145_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccr.2014.03.015","volume":"25","author":"HJ Clarke","year":"2014","unstructured":"Clarke, H. J., Chambers, J. E., Liniker, E. & Marciniak, S. J. Endoplasmic reticulum stress in malignancy. Cancer Cell. 25, 563\u2013573 (2014).","journal-title":"Cancer Cell."},{"key":"145_CR12","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1111\/febs.13598","volume":"283","author":"R Iurlaro","year":"2016","unstructured":"Iurlaro, R. & Munoz-Pinedo, C. Cell death induced by endoplasmic reticulum stress. FEBS. J. 283, 2640\u20132652 (2016).","journal-title":"FEBS. J."},{"key":"145_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/sj.embor.7400779","volume":"7","author":"E Szegezdi","year":"2006","unstructured":"Szegezdi, E., Logue, S. E., Gorman, A. M. & Samali, A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7, 880\u2013885 (2006).","journal-title":"EMBO Rep."},{"key":"145_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrm1052","volume":"4","author":"L Ellgaard","year":"2003","unstructured":"Ellgaard, L. & Helenius, A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4, 181\u2013191 (2003).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"145_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nature02262","volume":"426","author":"R Sitia","year":"2003","unstructured":"Sitia, R. & Braakman, I. Quality control in the endoplasmic reticulum protein factory. Nature 426, 891\u2013894 (2003).","journal-title":"Nature"},{"key":"145_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1126\/science.1209038","volume":"334","author":"P Walter","year":"2011","unstructured":"Walter, P. & Ron, D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 334, 1081\u20131086 (2011).","journal-title":"Science"},{"key":"145_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.1254312","volume":"345","author":"M Lu","year":"2014","unstructured":"Lu, M. et al. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science 345, 98\u2013101 (2014).","journal-title":"Science"},{"key":"145_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ncb3184","volume":"17","author":"C Hetz","year":"2015","unstructured":"Hetz, C., Chevet, E. & Oakes, S. A. Proteostasis control by the unfolded protein response. Nat. Cell Biol. 17, 829\u2013838 (2015).","journal-title":"Nat. Cell Biol."},{"key":"145_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.celrep.2015.09.016","volume":"13","author":"MCB Wielenga","year":"2015","unstructured":"Wielenga, M. C. B. et al. ER-stress-induced differentiation sensitizes colon cancer stem cells to chemotherapy. Cell Rep. 13, 489\u2013494 (2015).","journal-title":"Cell Rep."},{"key":"145_CR20","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ccell.2016.04.013","volume":"29","author":"M Cerezo","year":"2016","unstructured":"Cerezo, M. et al. Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance. Cancer Cell. 29, 805\u2013819 (2016).","journal-title":"Cancer Cell."},{"key":"145_CR21","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister, S. et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67, 1783\u20131792 (2007).","journal-title":"Cancer Res."},{"key":"145_CR22","doi-asserted-by":"publisher","first-page":"6297","DOI":"10.1182\/blood-2011-01-332379","volume":"117","author":"CM Shirley","year":"2011","unstructured":"Shirley, C. M. et al. Bortezomib induction of C\/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood 117, 6297\u20136303 (2011).","journal-title":"Blood"},{"key":"145_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13287-016-0282-7","volume":"7","author":"L Cortes-Dericks","year":"2016","unstructured":"Cortes-Dericks, L., Froment, L., Kocher, G. & Schmid, R. A. Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines. Stem Cell Res. Ther. 7, 25 (2016).","journal-title":"Stem Cell Res. Ther."},{"key":"145_CR24","doi-asserted-by":"publisher","first-page":"8893","DOI":"10.18632\/oncotarget.2360","volume":"5","author":"A Kharbanda","year":"2014","unstructured":"Kharbanda, A. et al. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget 5, 8893\u20138905 (2014).","journal-title":"Oncotarget"},{"key":"145_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nprot.2008.226","volume":"4","author":"J Friedrich","year":"2009","unstructured":"Friedrich, J., Seidel, C., Ebner, R. & Kunz-Schughart, L. A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 4, 309\u2013324 (2009).","journal-title":"Nat. Protoc."},{"key":"145_CR26","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NA Franken","year":"2006","unstructured":"Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315\u20132319 (2006).","journal-title":"Nat. Protoc."},{"key":"145_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.195","volume":"6","author":"SQ Liang","year":"2015","unstructured":"Liang, S. Q. et al. Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. Cell Death Dis. 6, e1824 (2015).","journal-title":"Cell Death Dis."},{"key":"145_CR28","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-16-0844","volume":"23","author":"L Wu","year":"2017","unstructured":"Wu, L. et al. Patient-derived xenograft establishment from human malignant pleural mesothelioma. Clin. Cancer Res. 23, 1060\u20131067 (2017).","journal-title":"Clin. Cancer Res."},{"key":"145_CR29","doi-asserted-by":"publisher","first-page":"8352","DOI":"10.1073\/pnas.0907676107","volume":"107","author":"V Vaira","year":"2010","unstructured":"Vaira, V. et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl Acad. Sci. Usa. 107, 8352\u20138356 (2010).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"145_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.addr.2014.03.001","volume":"69-70","author":"CR Thoma","year":"2014","unstructured":"Thoma, C. R., Zimmermann, M., Agarkova, I., Kelm, J. M. & Krek, W. 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv. Drug Deliv. Rev. 69-70, 29\u201341 (2014).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"145_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jcp.24683","volume":"230","author":"M Ravi","year":"2015","unstructured":"Ravi, M., Paramesh, V., Kaviya, S. R., Anuradha, E. & Solomon, F. D. 3D cell culture systems: advantages and applications. J. Cell. Physiol. 230, 16\u201326 (2015).","journal-title":"J. Cell. Physiol."},{"key":"145_CR32","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/0008-5472.CAN-13-1747","volume":"74","author":"R Martin-Perez","year":"2014","unstructured":"Martin-Perez, R. et al. Activated ERBB2\/HER2 licenses sensitivity to apoptosis upon endoplasmic reticulum stress through a PERK-dependent pathway. Cancer Res. 74, 1766\u20131777 (2014).","journal-title":"Cancer Res."},{"key":"145_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2016.12.007","volume":"103","author":"GS Kaplan","year":"2017","unstructured":"Kaplan, G. S., Torcun, C. C., Grune, T., Ozer, N. K. & Karademir, B. Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect. Free Radic. Biol. Med. 103, 1\u201313 (2017).","journal-title":"Free Radic. Biol. Med."},{"key":"145_CR34","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.cellsig.2007.01.001","volume":"19","author":"M Martinez-Velazquez","year":"2007","unstructured":"Martinez-Velazquez, M., Melendez-Zajgla, J. & Maldonado, V. Apoptosis induced by cAMP requires Smac\/DIABLO transcriptional upregulation. Cell. Signal. 19, 1212\u20131220 (2007).","journal-title":"Cell. Signal."},{"key":"145_CR35","doi-asserted-by":"publisher","first-page":"31289","DOI":"10.1074\/jbc.M702777200","volume":"282","author":"D Chandra","year":"2007","unstructured":"Chandra, D., Choy, G. & Tang, D. G. Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release - evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase. J. Biol. Chem. 282, 31289\u201331301 (2007).","journal-title":"J. Biol. Chem."},{"key":"145_CR36","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/sj.cdd.4402134","volume":"14","author":"JI Semple","year":"2007","unstructured":"Semple, J. I., Smits, V. A., Fernaud, J. R., Mamely, I. & Freire, R. Cleavage and degradation of Claspin during apoptosis by caspases and the proteasome. Cell Death Differ. 14, 1433\u20131442 (2007).","journal-title":"Cell Death Differ."},{"key":"145_CR37","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1038\/sj.onc.1210560","volume":"26","author":"G Ceballos-Cancino","year":"2007","unstructured":"Ceballos-Cancino, G., Espinosa, M., Maldonado, V. & Melendez-Zajgla, J. Regulation of mitochondrial Smac\/DIABLO-selective release by survivin. Oncogene 26, 7569\u20137575 (2007).","journal-title":"Oncogene"},{"key":"145_CR38","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0006-2952(02)01155-3","volume":"64","author":"JP Piret","year":"2002","unstructured":"Piret, J. P., Mottet, D., Raes, M. & Michiels, C. Is HIF-1 alpha a pro- or an anti-apoptotic protein? Biochem. Pharmacol. 64, 889\u2013892 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"145_CR39","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jcp.2003.015032","volume":"57","author":"AE Greijer","year":"2004","unstructured":"Greijer, A. E. & van der Wall, E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J. Clin. Pathol. 57, 1009\u20131014 (2004).","journal-title":"J. Clin. Pathol."},{"key":"145_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Novel insights into mesothelioma biology and implications for therapy. Nat. Rev. Cancer 17, 475\u2013488 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"145_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/TCRM.S1603","volume":"4","author":"RK Goudar","year":"2008","unstructured":"Goudar, R. K. Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma. Ther. Clin. Risk. Manag. 4, 205\u2013211 (2008).","journal-title":"Ther. Clin. Risk. Manag."},{"key":"145_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.21037\/atm.2017.04.13","volume":"5","author":"BCJ Cho","year":"2017","unstructured":"Cho, B. C. J. The rationale for neoadjuvant radiation therapy in malignant pleural mesothelioma: how smart is SMART? Ann. Transl. Med. 5, 247 (2017).","journal-title":"Ann. Transl. Med."},{"key":"145_CR43","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","volume":"16","author":"RA Stahel","year":"2015","unstructured":"Stahel, R. A. et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 16, 1651\u20131658 (2015).","journal-title":"Lancet Oncol."},{"key":"145_CR44","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure, T. et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 12, 763\u2013772 (2011).","journal-title":"Lancet Oncol."},{"key":"145_CR45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lungcan.2015.05.014","volume":"89","author":"RA Damhuis","year":"2015","unstructured":"Damhuis, R. A. et al. Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England. Lung Cancer 89, 212\u2013217 (2015).","journal-title":"Lung Cancer"},{"key":"145_CR46","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao, A. S., Wistuba, I., Roth, J. A. & Kindler, H. L. Malignant pleural mesothelioma. J. Clin. Oncol. 27, 2081\u20132090 (2009).","journal-title":"J. Clin. Oncol."},{"key":"145_CR47","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.celrep.2013.02.031","volume":"3","author":"J Heijmans","year":"2013","unstructured":"Heijmans, J. et al. ER stress causes rapid loss of intestinal epithelial stemness through activation of the unfolded protein response. Cell Rep. 3, 1128\u20131139 (2013).","journal-title":"Cell Rep."},{"key":"145_CR48","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1038\/onc.2016.326","volume":"36","author":"JF Lidth de Jeude van","year":"2017","unstructured":"van Lidth de Jeude, J. F. et al. Induction of endoplasmic reticulum stress by deletion of Grp78 depletes Apc mutant intestinal epithelial stem cells. Oncogene 36, 3397\u20133405 (2017).","journal-title":"Oncogene"},{"key":"145_CR49","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.15252\/embr.201744761","volume":"18","author":"YD Yoo","year":"2017","unstructured":"Yoo, Y. D. et al. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Rep. 18, 1671 (2017).","journal-title":"EMBO Rep."},{"key":"145_CR50","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615\u20132622 (1999).","journal-title":"Cancer Res."},{"key":"145_CR51","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-07-0536","volume":"13","author":"A Sartore-Bianchi","year":"2007","unstructured":"Sartore-Bianchi, A. et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin. Cancer Res. 13, 5942\u20135951 (2007).","journal-title":"Clin. Cancer Res."},{"key":"145_CR52","doi-asserted-by":"publisher","first-page":"e974463","DOI":"10.4161\/23723556.2014.974463","volume":"2","author":"F Obrist","year":"2015","unstructured":"Obrist, F., Manic, G., Kroemer, G., Vitale, I. & Galluzzi, L. Trial watch: proteasomal inhibitors for anticancer therapy. Mol. Cell. Oncol. 2, e974463 (2015).","journal-title":"Mol. Cell. Oncol."},{"key":"145_CR53","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1016\/j.ejca.2013.05.008","volume":"49","author":"ME O\u2019Brien","year":"2013","unstructured":"O\u2019Brien, M. E. et al. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). Eur. J. Cancer 49, 2815\u20132822 (2013).","journal-title":"Eur. J. Cancer"},{"key":"145_CR54","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","volume":"7","author":"DA Fennell","year":"2012","unstructured":"Fennell, D. A. et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J. Thorac. Oncol. 7, 1466\u20131470 (2012).","journal-title":"J. Thorac. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0145-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0145-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0145-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:37Z","timestamp":1684616557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0145-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0145-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,20]]},"assertion":[{"value":"1 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was supported by grants from the Swiss Cancer League (RWP) and the Cancer League of the Canton of Bern (RWP), PhD fellowship from China Scholarship Council (SQL and HY).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This study was approved by the Cantonal Ethics Committee of Bern, Switzerland, and has been performed in accordance with the Declaration of Helsinkihe.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}